First Clinical Trial Shows Graphene's Safety in Humans

In the first clinical trial of its kind, researchers found that short-term exposure to low concentrations of graphene nanoparticles appears to be tolerated by the human respiratory system. The study involved 14 volunteers who inhaled different concentrations of graphene oxide nanoparticles and showed no clear changes in their respiratory or cardiovascular systems, nor signs of inflammation. While this suggests graphene's safety, further research is needed to understand its long-term effects and interactions with the environment.